Hyperpolypharmacy and Readmission Risk Among Medicare Beneficiaries: The Role of Postdischarge Care

Why It Matters

Reducing readmissions lowers Medicare spending and improves quality metrics, making postdischarge TCM a strategic target for hospitals and payers seeking cost savings and better patient outcomes.

Key Takeaways

• Hyperpolypharmacy raises readmission odds modestly in older adults
• Postdischarge ambulatory visits cut 30‑day readmissions significantly
• Transitional care management (TCM) used by <15% of high‑risk patients
• Disability‑eligible Medicare beneficiaries face higher readmission rates
• Deprescribing and medication reconciliation can further reduce readmissions

Pulse Analysis

Hospital readmissions remain a costly quality indicator for the U.S. health system, accounting for billions of dollars in Medicare expenditures each year. Patients with multiple chronic conditions often receive extensive medication regimens, and when the count reaches ten or more drugs—a situation termed hyperpolypharmacy—the risk of adverse drug events and subsequent rehospitalization rises. While clinicians have long recognized the need for medication reconciliation, the evidence linking sheer medication count to readmission risk has been mixed, especially across diverse Medicare subpopulations such as older adults versus younger disabled beneficiaries.

The recent retrospective analysis of a 5 % national Medicare sample sheds new light on this debate. Using generalized estimating equations, the researchers showed that hyperpolypharmacy at admission modestly increased 30‑day readmission odds—by roughly 9 % after adjustment for comorbidities in the ≥65 cohort and by a non‑significant 2 % in the disability‑eligible group. More strikingly, any postdischarge ambulatory encounter lowered readmission risk, with transitional care management (TCM) visits delivering up to a 47 % odds reduction. Despite these benefits, only 14.8 % of older adults and 10.5 % of disabled beneficiaries with hyperpolypharmacy actually received TCM, highlighting a clear implementation gap.

For health systems and insurers, the findings suggest a high‑return opportunity: expanding TCM coverage and integrating deprescribing protocols could curb avoidable readmissions while improving patient safety. Payers may consider incentivizing providers through bundled payments or quality bonuses tied to postdischarge follow‑up rates. Meanwhile, policymakers should fund cost‑utility studies to quantify the financial upside of broader TCM adoption across Medicare segments. As value‑based care models mature, leveraging data‑driven insights on medication burden and care transitions will become essential for sustaining reimbursement and meeting increasingly stringent quality benchmarks.